CAR T-Cell Therapy: Recent Advances and Future Considerations
Patients with relapsed or refractory (R/R) cancers have a poor prognosis and limited treatment options. The recent approval of 2 chimeric antigen receptor (CAR) autologous T-cell products for R/R B-cell acute lymphoblastic leukemia and non-Hodgkin's lymphoma treatment is setting the stage for what is possible in other diseases. However, there are important factors that must be considered, including patient selection, toxicity management, and costs associated with CAR T-cell therapy. To begin to address these issues, NCCN organized a task force consisting of a multidisciplinary panel of experts in oncology, cancer center administration, and health policy, which met for the first time in March 2018. This webinar describes the current state of CAR T-cell therapy and future strategies that should be considered as the application of this novel immunotherapy expands and evolves.
This activity is designed to meet the needs of oncologists, hematologists, nurses, pharmacists, physician assistants, and other health care professionals treating patients on CAR T-cell therapy.
Following this activity, participants should be able to:
- Outline fundamental elements of chimeric antigen receptor (CAR) design and CAR T-cell therapy development
- Summarize key studies using CD19-targeted CAR T-cell therapy in relapsed/refractory B-cell malignancies
- Discuss preclinical and clinical strategies being developed for CAR T-cell therapy use in solid tumors
- Identify current and emerging management strategies for CAR T-cell therapy-associated toxicities
- Summarize recommended considerations for CAR T-cell persistence and disease surveillance
- Outline seminal components required to establish institutional CAR T-cell therapy programs
- Discuss current coverage/reimbursement structures and proposed reimbursement strategies for CAR T-cell therapy
Lihua E. Budde, MD, PhD
City of Hope National Medical Center
Elizabeth J. Shpall, MD
The University of Texas MD Anderson Cancer Center
Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
NCCN designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.25 hours of Category 1 credit for completing this activity.
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
NCCN designates this educational activity for a maximum of 1.25 contact hours.
|National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.|
NCCN designates this knowledge-based continuing education activity for 1.25 contact hours (0.125 CEUs) of continuing education credit. UAN: 0836-0000-18-131-L01-P
- 1.25 ACPE contact hours
- 1.25 AMA PRA Category 1 Credit™
- 1.25 ANCC contact hours
- 1.25 Participation
Click the Take Course button to register for this upcoming live webinar.
This webinar will be presented live one time only on Thursday, November 15, 2018, from 2:00 - 3:15 PM Eastern Standard Time (EST) (UTC -5). To convert the start time of this webinar for other time zones, click here.
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing